These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24618547)

  • 1. Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial.
    Seyfarth HJ; Hammerschmidt S; Halank M; Neuhaus P; Wirtz HR
    Pulm Circ; 2013 Sep; 3(3):632-8. PubMed ID: 24618547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ralinepag Phase II Open-Label Extension Study in Patients with Pulmonary Arterial Hypertension.
    Barberà J; Jansa P; Klings E; Ristić A; Keogh A; Solum D; Rao Y; Grover R; Saib I; Sood N
    Adv Ther; 2024 Mar; 41(3):1062-1074. PubMed ID: 38198043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase 5 inhibitors for pulmonary hypertension.
    Barnes H; Brown Z; Burns A; Williams T
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study).
    Ulrich S; Speich R; Domenighetti G; Geiser T; Aubert JD; Rochat T; Huber L; Treder U; Fischler M
    Swiss Med Wkly; 2007 Oct; 137(41-42):573-80. PubMed ID: 17990150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Riociguat for pulmonary arterial hypertension associated with congenital heart disease.
    Rosenkranz S; Ghofrani HA; Beghetti M; Ivy D; Frey R; Fritsch A; Weimann G; Saleh S; Apitz C
    Heart; 2015 Nov; 101(22):1792-9. PubMed ID: 26135803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial.
    Torres F; Farber H; Ristic A; McLaughlin V; Adams J; Zhang J; Klassen P; Shanahan W; Grundy J; Hoffmann I; Cabell C; Escribano Subías P; Sood N; Keogh A; D'Souza G; Rubin L
    Eur Respir J; 2019 Oct; 54(4):. PubMed ID: 31391223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial.
    Hoeper MM; Halank M; Wilkens H; Günther A; Weimann G; Gebert I; Leuchte HH; Behr J
    Eur Respir J; 2013 Apr; 41(4):853-60. PubMed ID: 22936711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of change in end tidal carbon dioxide after three minutes of step exercise between systemic sclerosis patients with and without pulmonary hypertension.
    Bernstein EJ; Gordon JK; Spiera RF; Huang WT; Horn EM; Mandl LA
    Rheumatology (Oxford); 2017 Jan; 56(1):87-94. PubMed ID: 28028158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.
    Guo J; Huang Y; Zhang X; Zhou F; Sun Y; Qin S; Ye Z; Wang H; Jappe A; Straub P; Pirotta N; Gogov S
    BMC Cancer; 2013 Mar; 13():136. PubMed ID: 23514360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riociguat therapy for pulmonary hypertension: a systematic review and meta-analysis.
    Wang L; Zhu L; Wu Y; Li Q; Liu H
    Ann Palliat Med; 2021 Oct; 10(10):11117-11128. PubMed ID: 34763472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
    J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of Macitentan in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension　- A Prospective, Multicenter, Open-Label, Single-Arm, Phase 3 Study.
    Sakurai S; Ukyo Y
    Circ Rep; 2021 Jul; 3(7):405-413. PubMed ID: 34250282
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of 6-min walk test distance vs. estimated maximum oxygen consumption for predicting postoperative pulmonary complications in patients undergoing upper abdominal surgery: a prospective cohort study.
    Yin X; Wang J; Xu Z; Qian F; Liu S; Cai Y; Jiang Z; Zhang X; Gu W
    Perioper Med (Lond); 2023 May; 12(1):18. PubMed ID: 37221581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term improvement in pulmonary hemodynamics is strongly predictive of long-term survival in patients with pulmonary arterial hypertension.
    Tiede H; Sommer N; Milger K; Voswinckel R; Bandorski D; Schermuly RT; Weissmann N; Grimminger F; Seeger W; Ghofrani HA
    Pulm Circ; 2013 Sep; 3(3):523-32. PubMed ID: 24618538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
    Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
    Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary arterial hypertension with below threshold pulmonary vascular resistance.
    Ratwatte S; Anderson J; Strange G; Corrigan C; Collins N; Celermajer DS; Dwyer N; Feenstra J; Keating D; Kotlyar E; Lavender M; Whitford H; Whyte K; Williams T; Wrobel JP; Keogh A; Lau EM;
    Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32341105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Marra AM; Egenlauf B; Ehlken N; Fischer C; Eichstaedt C; Nagel C; Bossone E; Cittadini A; Halank M; Gall H; Olsson KM; Lange TJ; Grünig E
    Int J Cardiol; 2015 Sep; 195():19-26. PubMed ID: 26011408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute hemodynamic effects of nebulized iloprost via the I-neb Adaptive Aerosol Delivery system in pulmonary hypertension.
    Richter MJ; Ghofrani HA; Voswinckel R; Seeger W; Schulz R; Reichenberger F; Gall H
    Pulm Circ; 2015 Mar; 5(1):162-70. PubMed ID: 25992279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations of Exercise Tolerance With Hemodynamic Parameters for Pulmonary Arterial Hypertension and for Chronic Thromboembolic Pulmonary Hypertension.
    Tsuboi Y; Tanaka H; Nishio R; Sawa T; Terashita D; Nakayama K; Satomi-Kobayashi S; Sakai Y; Emoto N; Hirata KI
    J Cardiopulm Rehabil Prev; 2017 Sep; 37(5):341-346. PubMed ID: 28671932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1): Multicenter, Early Feasibility Study.
    Rothman AMK; Vachiery JL; Howard LS; Mikhail GW; Lang IM; Jonas M; Kiely DG; Shav D; Shabtay O; Avriel A; Lewis GD; Rosenzweig EB; Kirtane AJ; Kim NH; Mahmud E; McLaughlain VV; Chetcuti S; Leon MB; Ben-Yehuda O; Rubin LJ
    JACC Cardiovasc Interv; 2020 Apr; 13(8):989-999. PubMed ID: 32327095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.